Planned development of inhaled triple therapy QVM149 for asthma

1 Planned development of inhaled triple therapy QVM149 for asthma Tokyo, Japan, June 18, 2015 – Sosei Group Corporation (“Sosei”; TSE Mothers Index:4565) confirms the plan to be announced later today by Novartis at a “Meet Novartis Management” investor event in Boston, USA to develop a new inhaled triple therapy for patients with moderate to severe asthma uncontrolled by standard ICS/LABA medication. QVM149 is a fixed dose, once daily combination of the long-acting beta 2-agonist (LABA) indacaterol, the long-acting muscarinic antago nist (LAMA) glycopyrronium bromide and the inhaled corticosteroid (ICS) mometasone fuorate. First regulatory filings of QVM149 are planned for 2018. Glycopyrronium bromide was licensed exclusively to Novartis in April 2005 by Sosei and its co-development partner Vectura. Under the terms of the Licence Agreement, Sosei is eligible to receive development, filing and approval milestones. In addition, Sosei will re ceive royalties on QVM149 sales in the event of a successful product launch. -Ends- Enquiries: Sosei Group Corporation Tokyo Office London Office Milica STOJKOVIC, Corporate Communication Kathryn LYDON, Corporate Communication +81-(0)3-5210-3399 +44-(0)20-7691-0983 [email protected] [email protected] About Asthma Asthma is characterized by variable symptoms of wheeze, shortness of breath, chest tightness and/or cough and by variable expiratory airflow limitation. Risk factors for developing asthma include allergens, viruses, tobacco smoke and chemical irritants. In many patients symptoms may resolve s pontaneously or in response to medication, however continued exposure to allergens may lead to worsening of symptoms. Persistent symptoms can trigger inflammatory responses in the airways and can deteriorate the condition.1 Some 235 million people, both children and adults, currently suffer from asthma.2 About Sosei Sosei is a biopharmaceutical company originat ing from Japan but with global presence. Sosei’s primary business model is based on identifying novel and/or differentiated product assets or technology platforms and, through supporting these in preclinical and 2 clinical development and establishing commercial partnerships, advancing new medicines to patients worldwide. For mo re information about Sosei, please visit www.sosei.com/en. Reference: 1. Global Strategy for Asthma Management and Prevention, 2015 update. (http://www.ginasthma.org/) 2. WHO Fact sheet N o 307 (http://www.who.int/mediacentre/factsheets/fs307/en/) # # # Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forwardlooking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitor s. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The release as fetched from its publisher. nxera.life ↗